Detail akcie ValiRx Rg online

Business Summary: ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Financial Summary: BRIEF: For the six months ended 30 June 2025, ValiRx Plc revenues was not reported. Net loss decreased 14% to L838K. Lower net loss reflects Administrative expenses decrease of 13% to L828K (expense), Share-based payment charge decrease from L19K (expense) to L0K, Research and development decrease of 13% to L105K (expense).